

Pursuant to the provisions of article 226 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

INSIDE INFORMATION

Grifols reports that, as a consequence of Grifols' self-sufficiency programs* for its Biopharma businesses, its Board of Directors has decided to initiate a process to evaluate a potential Initial Public Offering ("**IPO**") in the United States of a portion of the shares of its subsidiary and parent of its U.S. Biopharma business.

Any such transaction remains subject to, among other things, regulatory and legal requirements, internal approvals and market conditions. There can be no assurance that any IPO will be undertaken or completed by the company.

Regardless of any such IPO being undertaken or completed, Grifols will continue to trade in Spain through the automated information system (*mercado continuo*).

This communication and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction. No offer or sale of securities would be made absent registration under the Securities Act in compliance with the relevant U.S. securities laws.

In Barcelona, on 24 March 2026.

Laura de la Cruz Galán
Secretary to the Board of Directors

* Territories capable of supplying themselves with medicines derived from plasma without need of external supply.